PLEASANTON, Calif., Nov. 15, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) will announce financial results for its third quarter, which ended October 31, 2023, after market close on December 6, 2023. Veeva will host a conference call and webcast that day at 2:00 p.m. PT (5:00 p.m. ET) to discuss its financial results.
Veeva will post prepared remarks to its investor relations website at https://ir.veeva.com approximately at 1:05 p.m. PT (4:05 p.m. ET). A webcast replay will be available on the website following the live event.
Event: | Veeva's Fiscal 2024 Third Quarter Results Conference Call |
Date: | Wednesday, December 6, 2023 |
Time: | 2:00 p.m. PT (5:00 p.m. ET) |
Conference Call Registration: https://conferencingportals.com/event/badXudFz | |
Webcast: |
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor Veeva's investor relations website in addition to following its press releases, SEC filings, and public conference calls and webcasts.
Investor Relations Contact: | ||
Gunnar Hansen Veeva Systems Inc. 267-460-5839 This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact: Maria Scurry |
Last Trade: | US$281.35 |
Daily Change: | -2.85 -1.00 |
Daily Volume: | 982,787 |
Market Cap: | US$45.980B |
July 23, 2025 June 25, 2025 June 11, 2025 June 04, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load